Claims for Patent: 5,801,235

Summary for Patent: 5,801,235

Title:	Oligonucleotides with anti-cytomegalovirus activity
Abstract:	Disclosed are synthetic oligonucleotides 15 to 50 nucleotides in length which are specifically hybridizable with at least a portion of RNA or DNA derived from the UL36, UL84, UL101x-102, or UL112-113 genes of a cytomegalovirus. Also disclosed are pharmaceutical compositions including an oligonucleotide of the invention and methods of inhibiting cytomegalovirus infection using such oligonucleotides.
Inventor(s):	Pari; Gregory S. (North Smithfield, RI)
Assignee:	Hybridon, Inc. (Cambridge, MA)
Application Number:	08/249,386
Patent Claims:	1. A synthetic oligonucleolide which binds specifically to an mRNA encoding the UL36, UL84, UL101x-102, or UL112-113 genes of a human cytomegalovirus, the oligonucleotide binding to a portion of the mRNA which is complementary to SEQ. ID. NOS: 1, 2, 3, 4, 5, 6, 7, 8, or 9, wherein the binding inhibits cytomegalovirus replication. 2. The oligonucleotide of claim 1 further comprising at least one modified internucleoside linkage, at least modified sugar moiety, or at least one modified internucleoside linkage and at least one modified sugar moiety. 3. The oligonucleotide of claim 2 wherein the modified intemucleoside linkage is selected from the group consisting of phosphorothioate, alkylphosphonate, and combinations thereof. 4. The modified oligonucleotide of claim 2 wherein the modified sugar moiety comprises a 2'-O-methyl group. 5. The oligonucleotide of claim 1 which is about 15-30 nucleotides in length. 6. The oligonucleotide of claim 1 which comprises at least one deoxyribonucleotide. 7. The oligonucleotide of claim 1 which comprises at least one ribonucleotide. 8. The oligonucleotide of claim 7 further comprising at least one 2'-O-methyl group. 9. The oligonucleotide of claim 6 which comprises at least one ribonucleotide. 10. The oligonucleotide of claim 9 further comprising at least one 2'-O-methyl group. 11. The oligonucleotide of claim 1 which hybridizes to an intron/exon boundary of UL36. 12. The oligonucleotide of claim 11 consisting of the nucleic acid sequence set forth in Sequence Listing as SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. 13. The oligonucleotide of claim 1 which hybridizes to the putative translational start region of UL84. 14. The oligonucleotide of claim 13 consisting of the nucleic acid sequence set forth in the Sequence Listing as SEQ ID NO:4, or SEQ ID NO:5. 15. The oligonucleotide of claim 1 which hybridizes to the putative translational start region of UL101x. 16. The oligonucleotide of claim 15 consisting of the nucleic acid sequence set forth in the Sequence Listing as SEQ ID NO:6. 17. The oligonucleotide of claim 1 which hybridizes to an intron/exon boundary of UL112-113. 18. The oligonucleotide of claim 17 consisting of the nucleic acid sequence set forth in the Sequence Listing as SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9.

Details for Patent 5,801,235

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26